28003511|t|Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes
28003511|a|There is considerable debate about the benefits and risks of electronic cigarettes (ECs). To better understand the risk-benefit ratio of ECs, more information is needed about net nicotine consumption and toxicant exposure of cigarette smokers switching to ECs. Forty cigarette smokers (>1 year of smoking) interested in switching to ECs but not necessarily quitting smoking were enrolled in a four- week observational study and provided an e-Go C non-variable battery and refillable atomizers and choice of 8 flavors in 12 or 24 mg nicotine dosage. Measurement of urinary cotinine (metabolite of nicotine), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; a pulmonary carcinogen), and eight volatile organic compounds (VOCs) that are toxic tobacco smoke constituents was conducted at baseline and Week -4. All participants with follow-up data (92.5%) reported using the study EC. Of the 40 smokers, 16 reported no cigarettes at Week -2 (40%) and 6 continued to report no cigarettes at Week -4 (15%). Change in nicotine intake over the 4- weeks was non-significant (p=0.90). Carbon monoxide (p<0.001), NNAL (p<0.01) and metabolites of benzene (p < 0.01) and acrylonitrile (p=0.001) were significantly decreased in the study sample. Smokers switching exclusively to ECs for at least half of the study period demonstrated significant reductions in HEMA (p>=0.03) and AAMA (p<0.01). Smokers using ECs over 4- weeks maintained cotinine levels and experienced significant reductions in carbon monoxide, NNAL, and two out of eight measured VOC metabolites. Those who switched exclusively to ECs for at least half of the study period significantly reduced two additional VOCs. This study extends current literature by measuring change in smoking dependence and disease-associated biomarkers, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and a panel of eight common volatile organic compounds (VOCs) that are toxic tobacco smoke constituents in smokers who switch to electronic cigarettes. The findings support the idea of harm reduction, however some levels of toxicant exposure are still of clinical concern, particularly for dual users. Extrapolation of these results must be careful to separate the different toxic exposure results for exclusive switchers versus dual cigarette + EC users, and not to equate harm reduction with the idea that using ECs is harmless.
28003511	0	19	Tobacco Consumption	T055	C0543414
28003511	24	32	Toxicant	T131	C0599787
28003511	33	41	Exposure	T080	C0332157
28003511	45	54	Cigarette	T073	C0677453
28003511	55	62	Smokers	T033	C0337664
28003511	69	90	Electronic Cigarettes	T203	C3849993
28003511	113	119	debate	T052	C0870392
28003511	130	148	benefits and risks	T080	C0687742
28003511	152	173	electronic cigarettes	T203	C3849993
28003511	175	178	ECs	T203	C3849993
28003511	206	224	risk-benefit ratio	UnknownType	C0683155
28003511	228	231	ECs	T203	C3849993
28003511	238	249	information	T078	C1533716
28003511	270	278	nicotine	T109,T131	C0028040
28003511	279	290	consumption	T169	C1512806
28003511	295	303	toxicant	T131	C0599787
28003511	304	312	exposure	T080	C0332157
28003511	316	325	cigarette	T073	C0677453
28003511	326	333	smokers	T033	C0337664
28003511	347	350	ECs	T203	C3849993
28003511	358	367	cigarette	T073	C0677453
28003511	368	375	smokers	T033	C0337664
28003511	380	384	year	T079	C0439234
28003511	388	395	smoking	T055	C0037369
28003511	397	407	interested	T041	C0543488
28003511	424	427	ECs	T203	C3849993
28003511	448	464	quitting smoking	T055	C0085134
28003511	490	494	week	T079	C0439230
28003511	495	514	observational study	T062	C1518527
28003511	531	558	e-Go C non-variable battery	T073	C3273359
28003511	563	583	refillable atomizers	T074	C0004185
28003511	600	607	flavors	T167	C0475332
28003511	623	631	nicotine	T109,T131	C0028040
28003511	632	638	dosage	T081	C0178602
28003511	640	671	Measurement of urinary cotinine	T059	C1278256
28003511	673	683	metabolite	T123	C0870883
28003511	687	695	nicotine	T109,T131	C0028040
28003511	698	743	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	T109,T131	C0389836
28003511	745	749	NNAL	T109,T131	C0389836
28003511	753	762	pulmonary	T023	C0024109
28003511	763	773	carcinogen	T131	C0007090
28003511	786	812	volatile organic compounds	T109	C2350439
28003511	814	818	VOCs	T109	C2350439
28003511	829	834	toxic	T080	C1407029
28003511	835	842	tobacco	T109,T131	C0040329
28003511	843	848	smoke	T131	C0037366
28003511	849	861	constituents	T167	C0729650
28003511	892	896	Week	T079	C0439230
28003511	905	917	participants	T098	C0679646
28003511	923	932	follow-up	T058	C1522577
28003511	933	937	data	T078	C1511726
28003511	965	970	study	T062	C2603343
28003511	971	973	EC	T203	C3849993
28003511	985	992	smokers	T033	C0337664
28003511	1009	1019	cigarettes	T073	C0677453
28003511	1023	1027	Week	T079	C0439230
28003511	1066	1076	cigarettes	T073	C0677453
28003511	1080	1084	Week	T079	C0439230
28003511	1105	1113	nicotine	T109,T131	C0028040
28003511	1114	1120	intake	T169	C1512806
28003511	1133	1138	weeks	T079	C0439230
28003511	1169	1184	Carbon monoxide	T131,T197	C0007018
28003511	1196	1200	NNAL	T109,T131	C0389836
28003511	1214	1225	metabolites	T123	C0870883
28003511	1229	1236	benzene	T109,T131	C0005036
28003511	1252	1265	acrylonitrile	T109,T131	C0001223
28003511	1281	1294	significantly	T078	C0750502
28003511	1295	1304	decreased	T081	C0205216
28003511	1312	1317	study	T062	C2603343
28003511	1326	1333	Smokers	T033	C0337664
28003511	1359	1362	ECs	T203	C3849993
28003511	1388	1393	study	T062	C2603343
28003511	1394	1400	period	T079	C1948053
28003511	1414	1425	significant	T078	C0750502
28003511	1426	1436	reductions	T080	C0392756
28003511	1440	1444	HEMA	T131	C1254354
28003511	1459	1463	AAMA	T131	C1254354
28003511	1474	1481	Smokers	T033	C0337664
28003511	1488	1491	ECs	T203	C3849993
28003511	1500	1505	weeks	T079	C0439230
28003511	1517	1532	cotinine levels	T059	C0202363
28003511	1549	1560	significant	T078	C0750502
28003511	1561	1571	reductions	T080	C0392756
28003511	1575	1590	carbon monoxide	T131,T197	C0007018
28003511	1592	1596	NNAL	T109,T131	C0389836
28003511	1592	1596	NNAL	T109,T131	C0389836
28003511	1619	1627	measured	T080	C0444706
28003511	1628	1631	VOC	T109	C2350439
28003511	1632	1643	metabolites	T123	C0870883
28003511	1679	1682	ECs	T203	C3849993
28003511	1708	1713	study	T062	C2603343
28003511	1714	1720	period	T079	C1948053
28003511	1721	1734	significantly	T078	C0750502
28003511	1735	1742	reduced	T080	C0392756
28003511	1758	1762	VOCs	T109	C2350439
28003511	1769	1774	study	T062	C2603343
28003511	1783	1801	current literature	T170	C0023866
28003511	1805	1814	measuring	T080	C0444706
28003511	1825	1832	smoking	T055	C0037369
28003511	1833	1843	dependence	T048	C0439857
28003511	1848	1877	disease-associated biomarkers	T201	C0005516
28003511	1879	1924	4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	T109,T131	C0389836
28003511	1926	1930	NNAL	T109,T131	C0389836
28003511	1960	1986	volatile organic compounds	T109	C2350439
28003511	1988	1992	VOCs	T109	C2350439
28003511	2003	2008	toxic	T080	C1407029
28003511	2009	2016	tobacco	T109,T131	C0040329
28003511	2017	2022	smoke	T131	C0037366
28003511	2023	2035	constituents	T167	C0729650
28003511	2039	2046	smokers	T033	C0337664
28003511	2061	2082	electronic cigarettes	T203	C3849993
28003511	2117	2131	harm reduction	T061	C0679771
28003511	2156	2164	toxicant	T131	C0599787
28003511	2165	2173	exposure	T080	C0332157
28003511	2187	2203	clinical concern	T078	C2699424
28003511	2307	2312	toxic	T080	C1407029
28003511	2313	2321	exposure	T080	C0332157
28003511	2322	2329	results	T169	C1274040
28003511	2366	2375	cigarette	T073	C0677453
28003511	2378	2380	EC	T203	C3849993
28003511	2406	2420	harm reduction	T061	C0679771
28003511	2446	2449	ECs	T203	C3849993